Marinomed Biotech AG: Capital Increase and 2025 Financial Outlook

Marinomed Biotech AG plans to raise at least €2 million through a capital increase to address delayed revenues from its primary source, Carragelose. The company aims to secure up to €6.4 million, offering shareholders a 4:1 share purchase opportunity at €14 per share, representing a 19% discount to the last 3 months' VWAP. These funds will help bridge a short-term liquidity gap, especially with a €1.32 million creditor repayment due in May 2026.

Despite revenue delays, Marinomed management remains optimistic about meeting operational earn-out targets of up to €10 million. Shareholders may benefit if payments arrive from operational or financial milestones, or Budesolv deals, allowing them to increase their stake at favorable terms. First Berlin Equity Research maintains a Buy rating for Marinomed, with a price target of €50, implying a 233% upside.